Neurotrope Inc. (NASDAQ:NTRP) and Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurotrope Inc.	N/A	0.00	11.02M	-1.47	0.00
Ligand Pharmaceuticals Incorporated	251.45M	10.52	143.32M	5.64	21.77

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Neurotrope Inc. and Ligand Pharmaceuticals Incorporated.

Profitability

Table 2 shows us the return on equity, net margins and return on assets of both companies.

	Net Margins	Return on Equity	Return on Assets
Neurotrope Inc.	0.00%	-93.4%	-84%
Ligand Pharmaceuticals Incorporated	57.00%	21.6%	8.9%

Volatility & Risk

Neurotrope Inc. has a beta of 2.83 and its 183.00% more volatile than S&P 500. Competitively, Ligand Pharmaceuticals Incorporated’s beta is 1.38 which is 38.00% more volatile than S&P 500.

Liquidity

The Current Ratio of Neurotrope Inc. is 6.4 while its Quick Ratio stands at 6.4. The Current Ratio of rival Ligand Pharmaceuticals Incorporated is 2.2 and its Quick Ratio is has 2.2. Neurotrope Inc. is better equipped to clear short and long-term obligations than Ligand Pharmaceuticals Incorporated.

Analyst Ratings

Recommendations and Ratings for Neurotrope Inc. and Ligand Pharmaceuticals Incorporated can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Neurotrope Inc.	0	0	0	0.00
Ligand Pharmaceuticals Incorporated	0	0	2	3.00

On the other hand, Ligand Pharmaceuticals Incorporated’s potential upside is 71.64% and its consensus target price is $222.

Institutional & Insider Ownership

Institutional investors owned 26.8% of Neurotrope Inc. shares and 0% of Ligand Pharmaceuticals Incorporated shares. About 25.36% of Neurotrope Inc.’s share are owned by insiders. Competitively, 2.1% are Ligand Pharmaceuticals Incorporated’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Neurotrope Inc.	-15.67%	2.83%	-26.97%	-51.72%	-49.24%	22.13%
Ligand Pharmaceuticals Incorporated	-0.66%	3.89%	-24.58%	-52.2%	-20.61%	-9.59%

For the past year Neurotrope Inc. has 22.13% stronger performance while Ligand Pharmaceuticals Incorporated has -9.59% weaker performance.

Summary

Ligand Pharmaceuticals Incorporated beats on 9 of the 11 factors Neurotrope Inc.

Neurotrope, Inc., a biopharmaceutical company, focuses on developing therapeutic and diagnostic technologies in the field of neurodegenerative diseases in the United States. The companyÂ’s lead product candidate is bryostatin-1, a natural product isolated from a marine invertebrate organism, which is in a Phase II trial for the treatment of moderate to severe AlzheimerÂ’s dementia, as well as in preclinical studies as a treatment for Fragile X Syndrome, Niemann-Pick Type C disease, and Rett Syndrome. It has a license agreement with the Leland Stanford Junior University to sublicense Bryologs that are structural derivatives of Bryostatin for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardioprotection, and traumatic brain injury; and technology license and services agreement with Cognitive Research Enterprises, Inc. and its affiliate, NRV II, LLC. The company was founded in 2012 and is based in New York, New York.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. The companyÂ’s partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others. Its internal development program comprise products for the treatment of Type 2 diabetes mellitus, oncology, allergy, anti-coagulant, depression, sun damage, blood disorders, and diabetes. The company is also involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated has alliances, licenses, and other business relationships with various pharmaceutical companies, including Novartis AG; Amgen, Inc.; Merck & Co., Inc.; Pfizer Inc.; Celgene; Gilead Sciences; Janssen Biotech, Inc.; Baxter International, Inc.; and Eli Lilly and Company. The company was founded in 1987 and is headquartered in San Diego, California.